Mylan to Introduce Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.

Article Link: Mylan to Introduce Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.

HERTFORDSHIRE, England and PITTSBURGH, March 2, 2018 /PRNewswire/ — Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will launch a new HIV treatment, Symfi Lo, which was approved in February by the U.S. Food and Drug…

Source: FDA New Drug Approvals